May 09, 2025

Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026

The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at...

The ASCO Post

May 07, 2025

Survival Trends in Melanoma Brain Metastases: Update of Melanoma Graded Prognostic Assessment

In a study reported in Journal of Clinical Oncology, Sperduto et al analyzed trends in survival associated with newly diagnosed melanoma brain metastases and updated the Melanoma Graded Prognostic Ass...

The ASCO Post

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post

September 19, 2023

Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab

In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues investigated the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodru...

The ASCO Post

January 05, 2024

Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer

Researchers investigated the potential of a rare subset of T cells to predict which patients with advanced skin cancer may be responsive to immunotherapy.

The ASCO Post

August 05, 2024

FDA Grants Accelerated Approval to T-Cell Therapy for Unresectable or Metastatic Synovial Sarcoma

On August 2, the FDA granted accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for a...

The ASCO Post

August 12, 2024

Pattern in Protein Production May Be Predictive of Side Effects From Immunotherapy in Patients With Melanoma

An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases may predict the occurrence of severe side effects from immunotherapy in patients with melanoma.

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

August 21, 2023

Ipilimumab Plus Nivolumab May Improve Outcomes in Patients With Refractory Metastatic Melanoma, Study Suggests

Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent s...

The ASCO Post